In the news release, TCBP Announces Shareholder Update Call on
March 5th 2024, issued 27-Feb-2024 by TC BioPharm over PR Newswire, we
are advised by the company that the first paragraph mention of the
shareholder update call time should read "4:30 p.m. ET" rather than
"10:00 am" as originally issued inadvertently. The complete,
corrected release follows:
TCBP Announces Shareholder Update Call on March 5th 2024
EDINBURGH, Scotland, Feb. 27,
2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer and other indications, today announced
that the company will host a shareholder update call on
Tuesday, March 5th, 2024, at
4:30 p.m. ET.
Management intends to provide a brief update on the Company's
operations, clinical trials as well as insight on the company's
2024 outlook and discuss business development efforts. The Company
intends to provide a forum for Q&A after remarks by CEO
Bryan Kobel.
Conference Call Information:
|
Date:
|
Tuesday, March 05,
2024
|
|
Time:
|
4:30 p.m.
Eastern Time
|
|
Live Call:
|
1-877-704-4453 (U.S. Toll-Free) or 1-201-389-0920
(International)
|
|
Webcast:
|
https://callme.viavid.com/viavid/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9MTM3MzU4ODMmaD10cnVlJmluZm89Y29tcGFueSZyPXRydWUmQj02
|
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of
acute myeloid leukemia using the Company's proprietary allogeneic
CryoTC technology to provide frozen product to clinics
worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tcbp-announces-shareholder-update-call-on-march-5th-2024-302072323.html
SOURCE TC BioPharm